Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

60%

3 of 5 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Early Phase 1
1(20.0%)
5Total
Phase 1(4)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06444048Phase 1Completed

Phase 1, Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of an Enterovirus D68-specific Monoclonal Antibody in Healthy Adults

Role: collaborator

NCT04473690Phase 1Completed

KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers

Role: lead

NCT04731818Early Phase 1Completed

An Exploratory Study of ZB-06 as a Vaginal Contraceptive Film

Role: lead

NCT02579083Phase 1Completed

Safety Study of Monoclonal Antibodies to Reduce the Vaginal Transmission of HSV and HIV

Role: lead

NCT04439695Phase 1Completed

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults

Role: lead

All 5 trials loaded